ALTSTATION.IO

Humana Inc. (HUM) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$195.15

Change

+0.83%

Market Cap

$23.47B

Avg Volume

1.7M

Company Overview

Humana Inc. provides a range of medical and specialty insurance products primarily in the United States. They focus on healthcare plans that include medical care, supplemental benefits, and pharmacy services. Their clientele spans individuals, employer groups, and government contracts, including Medicaid and Medicare programs. Humana also operates primary care centers and offers services such as home health and hospice care.

Humana is a significant player in the healthcare insurance sector, positioning itself as a market leader alongside competitors like UnitedHealth Group and Anthem. Their edge lies in a diversified portfolio that includes Medicare Advantage plans and a growing presence in home health services through the CenterWell division. However, they face challenges from rising healthcare costs and regulatory pressures, which can impact profit margins.

Currently, Humana is on a growth trajectory, focusing on expanding its services and integrating technology into its operations. Recent initiatives include partnerships in telehealth and advancements in pharmacy management. These strategic shifts position Humana to adapt to evolving market demands and enhance patient care, thus setting the foundation for continued growth in a competitive landscape.

Key Financials

Market Cap

$23.47B

Revenue

$126.36B

EBITDA

$3.86B

Gross Margin

14.9%

Profit Margin

1.0%

Revenue Growth

11.1%

Total Cash

$22.12B

Total Debt

$12.95B

Free Cash Flow

$1.58B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

18.27

Forward P/E

16.26

Beta

0.44

52-Week High

$315.35

52-Week Low

$186.00

EPS

$10.68

50-Day Avg

$251.10

200-Day Avg

$255.84

Price/Book

1.27

Technical Analysis

Over the past 52 weeks, Humana Inc. (HUM) has exhibited a clear downtrend, losing approximately 26.3% from its peak, indicating significant weakness. Key resistance is identified around the $260 level, as the stock has struggled to maintain its position above this mark, while a strong support level exists near $193.94, the lowest point reached in February. Notable price patterns include a series of lower highs and lower lows, culminating in a steep drop toward the year’s end, followed by a brief consolidation phase before the recent plunge. In recent weeks, momentum has shifted downward, with the stock hovering around the critical support area and showing flags of weak buying interest. Currently priced at $195.15, the stock is positioned near the lower end of its 52-week range, suggesting potential for continued downward pressure or a critical bounce if support holds. The proximity to this support level implies heightened volatility, making this an essential point for traders to monitor for possible reversal signals.

Recent News and Developments

Here are the latest news and developments for Humana Inc

(HUM) stock in the past week:

Market Update

### Morgan Stanley Downgrades Humana Due to Medicare Advantage Risks
Morgan Stanley downgraded Humana’s stock from “Equal-weight” to “Underweight” on February 2, 2026, significantly cutting its price target to $174 from $262. The downgrade was primarily attributed to policy risks and Humana’s 2026 Medicare Advantage bid strategy, which analysts believe could hinder the company’s margin turnaround

Market Update

### Humana Stock Hits New 52-Week Low Amid Analyst Downgrades and Regulatory Concerns
Humana’s stock experienced significant price movements, hitting a new 52-week low recently. On February 2, 2026, the stock was down 4.10% and traded around $187.20, having plummeted over 21% on January 27, 2026. This decline follows a series of analyst downgrades, including Zacks Research lowering Humana to a “st

Market Sentiment and Analyst Recommendations

Bull Case

Humana’s 11.1% revenue growth to $126.36B shows the core business is expanding despite sector headwinds. The stock is down 38% from its 52-week high, trading at 18.27x P/E — below historical averages for a diversified health insurer with this scale. The company’s $22.12B in cash against $12.95B in debt gives it significant financial flexibility to weather the Medicare Advantage reimbursement pressure and fund strategic pivots. Analyst targets range up to $353, suggesting the downside has been priced in by the market. The Zynex partnership demonstrates Humana is actively expanding into adjacent pain management revenue streams, which could offset MA margin compression. If the company stabilizes Star Ratings and Medicare Advantage membership stabilizes in 2027, the stock has 45% upside to the $282 consensus target.

Bear Case

Morgan Stanley’s downgrade to $174 (which is below current price) reflects a legitimate structural problem: Humana’s heavy MA exposure means it gets hit disproportionately by flat reimbursement rates. The Trump administration’s nearly flat 2027 benchmark rates versus market expectations of 3-5% growth destroy margin expansion plans. Q4 2025 earnings expected to show a -$4.01 loss per share is a massive red flag that underwriting losses are accelerating. The stock has already fallen 26.3% over 52 weeks and just hit a new low at $187.20 — this isn’t panic selling, it’s repricing the business model. Humana’s turnaround depends on improving Star Ratings and MA profitability in an environment where the government is actively reducing reimbursement. Until there’s evidence of margin stabilization or a clear pivot away from MA dependency, the downside risk remains real.

What to Watch

Q4 2025 earnings on February 11, 2026 will be the first real test of how bad the MA damage is. Look specifically for 2026 enrollment trends and any guidance cuts for 2027 — if management acknowledges the reimbursement headwind in their outlook, expect another 5-10% drop. Monitor the 2027 Medicare Advantage Advance Rate Notice closely; if CMS signals any improvement above flat reimbursement, that’s a reversal catalyst worth 15-20% upside. Track Star Ratings progress quarterly; Humana’s turnaround thesis hinges entirely on improving these scores to justify higher reimbursement. Support at $193.94 is critical — a break below that level suggests the stock is heading toward the $174 Morgan Stanley target. Watch for any strategic announcements about MA portfolio optimization or non-MA revenue expansion; management needs to show they’re actively de-risking the business, not just hoping for better reimbursement rates.

Analyst Consensus

HOLD

Based on 24 analyst opinions

Low Target

$174.00

Mean Target

$282.96

High Target

$353.00

Earnings and Financial Data

Sector

Healthcare

Industry

Healthcare Plans

Employees

65,680

Earnings & Dividends

Next Earnings

Feb 11, 2026

EPS (Trailing)

$10.68

Dividend Yield

183.0%

Payout Ratio

33.1%

Frequently Asked Questions

Is HUM a good stock to buy?

HUM is currently trading at $195.15 with a market cap of $23.47 billion and a P/E of 18.27. Analysts recommend a HOLD with a target price of $282.96, indicating potential upside but also uncertainty; tread carefully.

What is HUM’s price target?

The target price for HUM is set at $282.96, significantly higher than its current price of $195.15. This suggests that analysts believe there is room for growth, but investors should weigh the risks in the healthcare sector.

Does HUM pay a dividend?

Yes, Humana Inc. offers a dividend yield of 183.0%. This is an attractive feature for income-focused investors, but the unusually high yield warrants a deeper dive into its sustainability.

What is HUM’s 52-week range?

HUM’s stock has traded within a 52-week range of $186.00 to $315.35. This high volatility can present both opportunities and risks for investors looking to enter or exit positions.

What does HUM’s forward P/E indicate?

HUM’s forward P/E is 16.26, suggesting that the stock might be undervalued based on future earnings expectations. However, this must be weighed against market conditions and sector performance to make an informed decision.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.